This section has been created to share information about the HIV Medication Access Workgroup. This workgroup was a convened as a result of a budget proviso by the Legislature as presented on SB5092, section 118.6.a.
---
HIV PDL Medication Parity Proviso
Office of the Governor
(6)(a) $20,000 of the general fund—state appropriation for fiscal year 2022 is provided solely for the Washington state LGBTQ commission, in collaboration with the health care authority, department of health, advocates for people living with HIV in Washington, consumers, and medical professionals with expertise in serving the medicaid population living with HIV, to consider and develop recommendations regarding:
(i) Access to HIV antiretroviral drugs on the medicaid drug formulary, including short- and long-term fiscal implications of eliminating current prior authorization and fail-first requirements;
(ii) Impact of drug access on public health and the statewide goal of reducing HIV transmissions; and
(iii) Maximizing pharmaceutical drug rebates for HIV antiretroviral drugs.
(b) The commission shall submit a brief report with recommendations to the appropriate committees of the legislature by November 1, 2021.
---
If you are part of one of the stakeholder groups mentioned in the proviso and are interested in participating of the meetings or staying updated on the progress of this project, please fill out this form.
Please use the following link to access the meetings.
https://ofm-wa-gov.zoom.us/j/82798515979?pwd=TzZKcEoxazZ4R2sycVpuVkNJcWFOdz09
Meeting ID: 827 9851 5979
Passcode: 173957
Final Report
HIV Medication Access Workgroup Final Input Report - November 2021
Meeting Materials
First Meeting - August 23rd
- Blueprint of Report to Legislature (DRAFT - for public input)
- Video Recording of First Workgroup Meeting
Second Meeting - September 13th
- Video Recording of Second Workgroup Meeting
- Presentations:
• HIV Medication Management
• HIV Medication Pharmaceutical Rebates
• HIV Drug Utilization Data: State Comparison
• HIV Therapies Relative Costs
• HIV Drugs Cost Models
• Costs Assumptions Slide
Third Meeting - October 4th
- DRAFT: Blueprint of Final Report (for feedback from partners)
- Provide Feedback to the Blueprint of Final Report here.
- Video Recording of Third Workgroup Meeting
Presentations:
- Summary of Research on Efficacy of Single vs. Multiple Pills Regimens
Fourth Meeting - October 25th
- UPDATED DRAFT: Blueprint of Final Report (for input from partners)
Town Halls
- Notice of Public Town Hall Conversation - September 20th
- Agenda: Town Hall September 20th
- Recording of Town Hall Conversation on September 20th
- Notice of Public Town Hall Conversation - October 12th
- Agenda: Town Hall October 12th
- Recording of Town Hall Conversation on October 12th
- Notes from Town Hall Conversation on October 12th
Written Public Comments
- Testimony to Oct 12 2021 public town hall
- NMAC WA Open Access HIV Letter
Supporting Documents
- Operating Guidelines for Workgroup Meetings
- UPDATED Blueprint Draft for Workgroup Review
- Understanding the Medicaid Prescription Drug Rebate Program
- The Medicaid Drug Rebate Program and the impact of “best price” rules
- Drug Policy 101: Pharmaceutical Marketing Tactics
- 2015 HIV Related Disparities from Department of Health
- Washington State HIV Surveillance Report: 2020 edition
Other Resources
MAX Clinics in WA
Models of Care and Health Management
- Medicaid Self-Directed Services
Research on HIV/AIDS and Mental Health
- National Institute of Mental Health (NIMH): HIV/AIDS and Mental Health
- The Impact of Mental Health Across the HIV Care Continuum
- HIV and Psychiatric Comorbidities: What Do We Know and What Can We Do?
Research on Single vs. Multiple Pills Regimens
- Study on effectiveness of single vs. multiple pills regimen (2021): Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single-tablet regimen in a multicentre cohort in Spain